Recent urology trials more likely to include data on harmful effects of treatments

In recent years, clinical trial reports in major urology journals have been more likely to include data on harmful effects of treatments, reports a study in the January issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA).

Gilead makes another ADC move, inking up to $415M pact with Tubulis

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 4, 2024

Gliosarcoma drugs in development, 2023

GlobalData tracks 49 drugs in development for Gliosarcoma by 39 companies/universities/institutes. The top development phase for Gliosarcoma is phase i, with 22 drugs in that

December 1, 2023

Gene-editing field sees another merger, this time between Chroma Medicine and Nvelop Therapeutics

Two prominent gene-editing startups, Chroma Medicine and Nvelop Therapeutics, said Wednesday they will merge, forming a new company called nChroma Bio. The merger will combine

December 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.